3.780

-0.030 (-0.79%)
Range 3.550 - 3.840   (8.17%)
Open 3.810
Previous Close 3.810
Buy Price 3.700
Buy Volume 9
Sell Price 3.780
Sell Volume 9
Volume 707,614
Value -
Remark
Measurement Type Value
EPS (USD) -0.864
Trailing EPS (USD) -0.918
NAV (USD) 1.049
Cash In Hand (USD) 1.361
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 3.632
Price / Cash In Hand 2.8
Issued & Paid-up Shares 19,428,700
Treasury Shares -
Market Cap (M) 73.943
Par Value (USD) n.a.
Beta - 75 Days 0.739
R-Squared - 75 Days(%) 2.78
Beta - 500 Days 1.192
R-Squared - 500 Days(%) 0.2
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 28 Jul 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 04 Aug 2021
View All Events

About TRACON PHARMACEUTICALS INC

TRACON Pharmaceuticals Inc is a United States-based biopharmaceutical company which licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The Company�s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company focuses to become the oncology and ophthalmology therapeutics Company. Both TRC105 and TRC102 are being developed for treatment in combination with available therapies.

Loading Chart...